United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by California Public Employees Retirement System

California Public Employees Retirement System cut its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 1.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 209,204 shares of the biotechnology company's stock after selling 2,618 shares during the period. California Public Employees Retirement System owned about 0.47% of United Therapeutics worth $73,816,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in UTHR. Newbridge Financial Services Group Inc. bought a new position in shares of United Therapeutics in the 4th quarter worth $25,000. Millstone Evans Group LLC acquired a new stake in United Therapeutics in the fourth quarter valued at approximately $67,000. MassMutual Private Wealth & Trust FSB grew its holdings in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 58 shares during the last quarter. Jones Financial Companies Lllp increased its position in shares of United Therapeutics by 678.9% during the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock worth $104,000 after purchasing an additional 258 shares in the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of United Therapeutics during the 4th quarter valued at $131,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $896,950.62. The trade was a 79.51 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Tommy G. Thompson sold 2,500 shares of the firm's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the transaction, the director now owns 8,480 shares in the company, valued at $2,703,424. The trade was a 22.77 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 72,500 shares of company stock valued at $26,134,500. Company insiders own 11.90% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. HC Wainwright restated a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research note on Thursday, February 27th. UBS Group boosted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. Finally, StockNews.com cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $388.25.

United Therapeutics Stock Up 1.8 %

Shares of NASDAQ:UTHR traded up $5.38 during trading on Wednesday, hitting $312.26. 461,017 shares of the stock traded hands, compared to its average volume of 450,237. The company has a fifty day moving average price of $336.64 and a two-hundred day moving average price of $355.09. United Therapeutics Co. has a 52-week low of $227.75 and a 52-week high of $417.82. The company has a market cap of $14.02 billion, a price-to-earnings ratio of 13.71, a P/E/G ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. During the same period in the prior year, the company posted $4.36 EPS. On average, equities research analysts predict that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.